All News

Psoriasis Severe legs sara

Difficult-to-Treat Psoriasis

Jack Cush, MD

This meta-analysis of psoriasis treatments shows that biologic therapies may be less effective in certain psoriasis (PSO) patients, particularly those who are older, smokers, with higher BMI an prior exposure to biologics.

Read Article
mtx.png (keep)

No Risk of Interstitial Lung Disease with Methotrexate Use

Jack Cush, MD

JAMA reports a cohort study that investigated the association between methotrexate (MTX) use and Interstitial lung disease (ILD) in patients with dermatomyositis (DM).

Read Article
EULAR24,Roundup

EULAR 2024 Rheumatology Roundup (6.21.2024)

Jack Cush, MD

Drs. Artie Kavanaugh and Jack Cush discuss highlights from the EULAR 2024 meeting in Vienna

Read Article
psA.fil_.Hands_.jpg

Camels and psoriatic arthritis - a new treatment link

Antoni Chan, MD, PhD

I am a big fan of animals and wildlife. Whenever I can, I try to wander outdoors to look for our friends big and small in the animal kingdom. If it rains, as often it does in the UK, the latest edition of Planet Earth will do. So, I was naturally attracted to the presentation by Professor Iain McInnes from the University of Glasgow, oral presentation OP0195 at #EULAR2024 where the link between camels and psoriatic arthritis was made.

Read Article
RT: @synovialjoints In a Swedish-Danish cohort study on patients with PsA, treatment with TNFi was associated with a small increased risk of NMSC and with non-significant numeric risk increases for both BCC and SCC compared with bDMARD naïve #EULAR2024 Abstract 0150

Dr. John Cush RheumNow ( View Tweet)

Prevention of Psoriatic Arthritis Dr. Peter Nash sharing his perspectives on preventing psoriasis from turning into PsA at Eular 2024 in Vienna, Austria. https://t.co/DQJ5AcwchL https://t.co/lHtCt720D9

Links:

Dr. John Cush RheumNow ( View Tweet)
New indications for JAK inhibitors There are several new positive RCTs for JAK inhibitors. We are so familiar with RA, PsA, SpA, axSpA and non radiographic axSpA. https://t.co/L0QRj5ZWEE https://t.co/SdtuAahA13

Links:

Dr. John Cush RheumNow ( View Tweet)
PsA: Switch or Cycle, the Eternal Question Dr. Aurelie Najm reports on abstracts POS0278 and POS0266 presented at Eular 2024 in Vienna, Austria https://t.co/fBtoTQy5Wx https://t.co/rbvaqy0oyC

Links:

Dr. John Cush RheumNow ( View Tweet)
PsA: Switch or Cycle, the Eternal Question Dr. Aurelie Najm reports on abstracts POS0278 and POS0266 presented at Eular 2024 in Vienna, Austria. https://t.co/xA8YYCi94r https://t.co/RyS6vnlzam

Links:

Dr. John Cush RheumNow ( View Tweet)
Moonlake has announced its phase 3 program to develop Sonelokimab (M1095) a dual inhibitor of IL-17A & IL-17F for use in Psoriatic arthritis. IZAR-1 & IZAR-2 Ph 3 DBPCT will enroll 1,500 adults w/ active PsA, w/ ACR 50 endpoint at Week 16 https://t.co/NUZ3cc4bUx https://t.co/nGP10y3Kuw

Links:

Dr. John Cush RheumNow ( View Tweet)
Abbvie announced upadacitinib (Rinvoq) is approved for use in polyarticular JIA and Psoriatic Arthritis (in children 2 years of age and older who have had an inadequate response or intolerance to 1 or more tumor necrosis factor (TNF) blockers) https://t.co/I4Wu49xGxy https://t.co/nTwgfRG1qG

Links:

Dr. John Cush RheumNow ( View Tweet)
Camels and psoriatic arthritis - a new treatment link https://t.co/0SQt3UPmKu https://t.co/zvwH9iYtxX

Links:

Dr. John Cush RheumNow ( View Tweet)
#EULAR2024 LBA0009 Phase 3 Open label H2H RCT of Ixekizumab vs in jPsA & enthesitis-related arthritis showed similar ACR30 response rates at Wk16 (IXE=89%; ADA=95%). Open label and long-term follow up for IXE is ongoing to assess for sustainment @Yuz6Yusof https://t.co/eSqOkBGBK2
Dr. John Cush RheumNow ( View Tweet)
PsA Treatment: is Earlier Better? Dr. Aurelie Najm discusses abstract OP0184, presented at Eular 2024 in Vienna, Austria. https://t.co/l2M19PwhzP https://t.co/f3TGBVszU4

Links:

Dr. John Cush RheumNow ( View Tweet)
Transition from Psoriasis to PsA: Can we Prevent It? Dr. Aurelie Najm discusses abstract OP0010 presented at Eular 2024 in Vienna, Austria. https://t.co/MnHG9DgA3H https://t.co/Vht33gWVlC

Links:

Dr. John Cush RheumNow ( View Tweet)
EULAR 2024: Tuesday’s Topic Panel (PSA) with RheumNow https://t.co/j4I1bC9ROD

Links:

Dr. John Cush RheumNow ( View Tweet)

Can we prevent psoriatic arthritis? PsA affects up to 30% of PsO patients. Understanding factors that lead to PsA helps in early interventions. Most PsA patients have preceding PsO. https://t.co/03H4YrvxMe https://t.co/efUVaccSHn

Links:

Dr. John Cush RheumNow ( View Tweet)
Is Izokibep the new kid on the block in PsA? ➡️ IL-17A inhibitor ➡️ Complete resolution of enthesitis at 16w ➡️ Overall good safety data LBA0005 #EULAR2024 @RheumNow https://t.co/8htPOz9YCG

Links:

Mrinalini Dey DrMiniDey ( View Tweet)
RISK OF NON-MELANOMA SKIN CANCER WITH TNFi AND OTHER bDMARDs IN PATIENTS WITH PSORIATIC ARTHRITIS: A SWEDISH AND DANISH COHORT STUDY- despite having minimal sun 25% increase NMSC TNFis vs other bDMARDs - skin checks ! @RheumNow #EULAR2024

Peter Nash drpnash ( View Tweet)

EULAR Abstract Archive POS0894 (2024) SAFETY OF UPADACITINIB ACROSS RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS, AND AXIAL SPONDYLOARTHRITIS ENCOMPASSING 15,000 PATIENT-YEARS OF CLINICAL TRIAL DATA Reassuring 15000 pt yrs f/u RA PsA AS https://t.co/XWnzuVMlbn @RheumNow #EULAR2024

Links:

Peter Nash drpnash ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×